Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire September 5, 2018

ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

GlobeNewswire September 5, 2018

ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

GlobeNewswire August 15, 2018

ProQR Announces Financial Results for the Second Quarter of 2018

GlobeNewswire August 8, 2018

ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

GlobeNewswire August 1, 2018

ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

GlobeNewswire July 12, 2018

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

GlobeNewswire June 28, 2018

ProQR to Present at the JMP Life Sciences Conference

GlobeNewswire June 14, 2018

ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire June 12, 2018

ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

GlobeNewswire June 4, 2018

ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

GlobeNewswire May 23, 2018

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Benzinga.com  May 13, 2018

ProQR Announces Results for the First Quarter of 2018

GlobeNewswire May 9, 2018

ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

GlobeNewswire April 30, 2018

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire April 11, 2018

ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

GlobeNewswire April 10, 2018

ProQR to Present at Two Upcoming Conferences

GlobeNewswire April 3, 2018

ProQR to Present at Upcoming Investor Conference

GlobeNewswire March 5, 2018

ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update

GlobeNewswire February 28, 2018

ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer

GlobeNewswire February 27, 2018